At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 6, 2026 at 08:00 ET
Acrivon Therapeutics acquired ACR-525 (Phase 2-ready oral JAK1 inhibitor) and a preclinical PKCθ inhibitor program from Aqilion AB for an undisclosed cash consideration, with no future royalties or milestones. The deal establishes immunology and inflammation as a new strategic pillar alongside oncology, targeting eosinophilic esophagitis as the first indication. The transaction closed concurrently with signing and was approved by both companies' boards.
- Acrivon acquired ACR-525 (Phase 2-ready oral JAK1 inhibitor) and a preclinical PKCθ inhibitor program from Aqilion AB.
- Consideration was undisclosed cash with no future royalties or milestone obligations.
- Eosinophilic esophagitis (EoE) targeted as first potential indication using a Phase 2-ready formulation.
- Transaction closed concurrently with signing; approved by both boards.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access